
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. reported retail revenues of $255 million, reflecting an 8.1% sequential growth and a 7.8% increase year-over-year, indicating strong performance in the retail segment. The company is projected to significantly enhance its free cash flow (FCF), expecting to reach up to $210 million in 2025, up from $109 million in 2024, with recent FCF results showing positive trends for four consecutive quarters. Furthermore, the anticipated gross margin expansion, alongside robust year-over-year earnings per share growth in 2026, underscores a favorable outlook for the company's financial performance.
Bears say
Diebold Nixdorf Inc faces a negative outlook primarily due to technological missteps and an inability to innovate, which could adversely affect revenues and profitability within its key Banking segment. The company is also experiencing declining demand for its products amidst increasing competitive pricing pressure, further complicating its financial stability. Additionally, potential disruptions related to supply chain issues, tariff-related costs, and the challenges of managing liquidity are significant risks that may hinder the firm's performance moving forward.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares